(Q44982199)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25336084%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

meta-analysis

0 references

title

Pharmacokinetics of single-agent axitinib across multiple solid tumor types (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25336084%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25336084%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

2

Ezra E W Cohen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25336084%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Michael A Tortorici

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25336084%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Yazdi K Pithavala

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25336084%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

May Garrett

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25336084%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Sinil Kim

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25336084%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

John P Fruehauf

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25336084%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

22 October 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25336084%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

21 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25336084%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25336084%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25336084%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

1279-1289

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25336084%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00280-014-2606-6

21 February 2020

exact match

0 references

cites work

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Population pharmacokinetic analysis of axitinib in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Diagnosing model diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Population pharmacokinetic analysis of sorafenib in patients with solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Genetic contribution to variable human CYP3A-mediated metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6

Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2606-6